Company Product Description Indication Status
Phase I
Altimmune Inc., of Gaithersburg, Md. Nasoshield Intranasal anthrax vaccine Anthrax prophylaxis Completed enrollment of 42 healthy subjects; immunogenicity data expected in the fourth quarter of 2020
Everest Medicines Ltd., of Shanghai FGF-401 ATP-competitive, reversible-covalent inhibitor of FGFR4 Advanced solid tumors First of up to 70 patients treated in the phase Ib/II study testing FGF-401 plus Keytruda (pembrolizumab, Merck & Co. Inc.)
Oncopeptides AB, of Stockholm Melflufen  Peptide-drug conjugate targeting aminopeptidases Immunoglobulin light chain amyloidosis First patient enrolled in phase I/II study testing melflufen plus dexamethasone after at least 1 prior line of therapy
Phase II
Oncolys Biopharma Inc., of Tokyo Telomelysin (OBP-301)  Telomerase modulator Recurrent, inoperable head and neck cancer Investigator-initiated study planned to evaluate telomelysin plus Keytruda (pembrolizumab, Merck & Co. Inc.) and stereotactic radiation
Phase III
Ligand Pharmaceuticals Inc., of San Diego, and Cstone Pharmaceuticals Co. Ltd., of Suzhou, China CS-1001  Monoclonal antibody targeting PD-L1 First-line treatment of stage IV squamous and non-squamous non-small-cell lung cancer CS-1001 plus chemotherapy produced a progression-free survival of 7.8 months compared to 4.9 months for chemotherapy alone (p<0.0001)
Roche Holding AG, of Basel, Switzerland Tecentriq (atezolizumab) Monoclonal antibody targeting  PD-L1 First-line, PD-L1-positive, metastatic triple-negative breast cancer The Impassion131 study testing Tecentriq plus paclitaxel didn't meet the primary endpoint of progression-free survival; overall survival showed a negative trend
Satsuma Pharmaceuticals Inc., of South San Francisco STS-101 Intranasal dry powder formulation of dihydroergotamine mesylate Migraine Started enrollment in the 300-patient Ascend study to test the long-term safety of STS-101 as an as-needed acute treatment; secondary endpoints include efficacy evaluations

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments